Acumen Pharmaceuticals, Inc.
http://www.acumenpharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Acumen Pharmaceuticals, Inc.
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Finance Watch: Turnstone Biologics Launches 14th Biopharma IPO Of 2023
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
Positive Early Signs For Acumen’s Bid To Go Beyond Leqembi In Alzheimer’s
Phase I data shows the oligomer-targeting antibody was safe and effective, and Acumen will now move ahead to a potentially pivotal Phase II/III study in Alzheimer’s disease.
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice